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Abstract
Objective To evaluate the cost effectiveness of four
disease modifying treatments (interferon betas and
glatiramer acetate) for relapsing remitting and
secondary progressive multiple sclerosis in the United
Kingdom.
Design Modelling cost effectiveness.
Setting UK NHS.
Participants Patients with relapsing remitting
multiple sclerosis and secondary progressive multiple
sclerosis.
Main outcome measures Cost per quality adjusted
life year gained.
Results The base case cost per quality adjusted life
year gained by using any of the four treatments
ranged from £42 000 ($66 469; &61 630) to £98 000
based on efficacy information in the public domain.
Uncertainty analysis suggests that the probability of
any of these treatments having a cost effectiveness
better than £20 000 at 20 years is below 20%. The key
determinants of cost effectiveness were the time
horizon, the progression of patients after stopping
treatment, differential discount rates, and the price of
the treatments.
Conclusions Cost effectiveness varied markedly
between the interventions. Uncertainty around point
estimates was substantial. This uncertainty could be
reduced by conducting research on the true
magnitude of the effect of these drugs, the
progression of patients after stopping treatment, the
costs of care, and the quality of life of the patients.
Price was the key modifiable determinant of the cost
effectiveness of these treatments.
Introduction
Multiple sclerosis is a demyelinating disease of the cen›
tral nervous system.1 It is the most common cause of
neurological disability in young adults. Four types of
disease have been defined: benign or stable, relapsing
remitting, secondary progressive, and primary pro›
gressive multiple sclerosis. We evaluated the cost effec›
tiveness of four drugs for multiple sclerosis. We
assessed the effect of each drug against conventional
management.
Until the 1990s there was no disease modifying
treatment for multiple sclerosis. Management of the
disease consisted of symptom control, physiotherapy,
psychiatric and social support, and disability aids. At
present the only disease modifying therapies available
for relapsing remitting and secondary progressive
multiple sclerosis are interferon beta and glatiramer
acetate, which reduce the number of relapses and the
rate at which patients progress through the disease. Up
to 63 000 people in England and Wales have multiple
sclerosis, but this estimate may be low. Up to 30% of the
population with multiple sclerosis could be eligible for
treatment with these drugs.2
Four disease modifying therapies are licensed for
the treatment of relapsing remitting multiple sclerosis
in the United Kingdom: interferon beta›1a (6
MIU/week; Avonex, Biogen), interferon beta›1b (8
MIU/week; Betaferon, Schering Health), glatiramer
acetate (20 mg/week; Copaxone, Teva), interferon
beta›1a (22 ìg/week; Rebif, Serono), and interferon
beta›1a (44 ìg/week; Rebif). Interferon beta›1b is the
only drug licensed for the treatment of secondary pro›
gressive multiple sclerosis in the United Kingdom. The
Association of British Neurologists has set out eligibil›
ity criteria for treatment with interferon beta and glati›
ramer acetate (box 1).3
Many attempts have been made to estimate the cost
effectiveness of these treatments for multiple sclerosis.
Analyses have produced cost effectiveness estimates
ranging from over £1m per quality adjusted life year
(QALY) gained to cost saving.4–9 Owing to major flaws
in the modelling of the clinical course of multiple scle›
rosis, efficacy, discontinuation of treatment, mortality,
and the analysis of uncertainty, none of these estimates
can be considered robust.8 The Cost Effectiveness of
Multiple Sclerosis Therapies Study Group was
commissioned by the National Institute for Clinical
Excellence to undertake this economic assessment in
Box 1: Association of British Neurologists
eligibility criteria for treatment with interferon
beta and glatiramer acetate in multiple sclerosis
• Able to walk independently
• At least two major relapses in the past two years
• Aged at least 18 years
• No contraindications
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consultation with all stakeholders to its appraisals
process, using the best available evidence.
Methods
We constructed a model to simulate the clinical course
of the disease. Health states were defined according to
the Kurtzke expanded disability status scale (box 2).10
This scale measures disease progression in terms of
impairment and disability. We modelled disability
status from 0 to 10 for relapsing remitting multiple
sclerosis and from 2 to 10 for secondary progressive
multiple sclerosis.10
We assessed the clinical course of the disease, costs,
and utilities with and without treatment over 20 years.
Improvements on the scale are not possible in our
model.
Our model used an annual cycle length. Figure 1
shows the transitions between health states that are
possible during each cycle. Patients can remain in their
current health state, progress one or more states, die,
transit to a secondary progressive health state, or stop
treatment. Patients who stop treatment progress
according to the transition rates for conventional
management, retaining the benefits of treatment
achieved up to the point of stopping treatment.11
Progression and relapses
We derived disease progression rates under conven›
tional management from a large study conducted over
25 years, based on a sample population of more than
1000 patients with essentially untreated multiple
sclerosis. Enrolment to this study ended in 1984.11 12 We
excluded patients who were not eligible for treatment
according to licensed indications and the Association
of British Neurologists guidelines (see box 1).3
We derived relapse rates from a cohort study that
reported relapses for each year since diagnosis rather
than for each disability state.13 We used the transition
matrices for disease progression under conventional
management to calculate the expected time since diag›
nosis for each disability state. We then used these to
estimate the probability of relapse for each disability
state in the model.
Effectiveness
We derived relative risks of relapse and disease
progression from four published trials of interferon
beta and one trial of glatiramer acetate (table 1).14–18 In
addition we were able to reanalyse trial data held as
commercial in›confidence for three of the products to
produce alternate relative risks for relapse and disease
progression.19–20 We made all the results for efficacy and
cost effectiveness available to the appraisal committee
of the National Institute for Clinical Excellence; only
those derived from publicly available efficacy data and
those in›confidence results approved for publication
are reproduced here in full.
Costs
We estimated the costs of managing disability and
relapse in each health state from a UK based patient
dataset comprising 622 records.21 We excluded 244
records because the patient had primary progressive
multiple sclerosis, benign multiple sclerosis, or there
were no data on disability status. Management of
patients in state 3.0 was around twice as expensive as
management in state 1.0, management of patients in
state 7.0 was around 10 times as expensive as manage›
ment in state 3.0, and management in states 9.0 and 9.5
was twice as expensive as management in state 7.0.
The costs of interferon beta›1a (6 MIU/week 22
ìg/week, and 44 ìg/week) and glatiramer acetate (20
mg/week) were taken from the British National Formu›
lary according to licensed dosages.22 The cost of 8
MIU/week interferon beta›1b was obtained from the
manufacturer.
Health outcomes used in model
We obtained the quality of life for each disability state
and the disutility of relapses from a dataset of 1552
patients with multiple sclerosis in the United Kingdom.
The Multiple Sclerosis Research Trust made this data›
set available to the National Institute for Clinical Excel›
lence for the purposes of the appraisal.23 We used data
from patients with relapsing remitting multiple sclero›
sis and secondary progressive multiple sclerosis
(n=780). We used a generalised linear regression
model of EQ›5D single index score as a function of
type of multiple sclerosis, disability status, and relapse
status to estimate the utility for each disability state and
the disutility of relapse. We made the results on utility
available to the appraisal committee of the National
Institute for Clinical Excellence, however they are com›
Box 2: Kurtzke expanded disability status scale
• 0—normal neurological examination
• 1.0›3.5—neurological impairments that are likely to
have limited impact on the activities of daily living
• 4.0›5.5—ambulatory limitations for distances up to
500 m
• 6.0›9.5—require mobility aids. As disease progresses,
patients may require a wheelchair and eventually
become bedridden
• 10—death due to multiple sclerosis
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Fig 1 Model of transitions between health states of patients with relapsing remitting or
secondary progressive multiple sclerosis
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mercial in›confidence and are not reproduced here.
We estimated the difference between state 0 and state
3.0 to represent around a 30% reduction in the
patient’s quality of life. We found a similar reduction in
quality of life from state 3.0 to state 7.0; we estimated
that states 9.0 and 9.5 were worse than death—that is,
the quality of life was less than zero.
Discounting
Good practice requires that costs and benefits that
occur in the future are given less weight than those that
occur in the present; a process called discounting.24 In
keeping with recommendations from the UK Treasury,
we discounted costs at 6% per annum, and we
discounted quality of life benefits at 1.5% per annum
for the base case analysis.25 For information we present
the results when both costs and benefits are discounted
at 6%.
Model assumptions
Box 3 details the assumptions made in constructing
the model. The general principle maintained in these
assumptions is to favour the novel therapies within the
analysis.
In the base case scenario, patients start treatment
according to the Association of British Neurologist’s
guidelines and are treated until they reach disability
state 7.0. A 20 year time horizon is used, with patients
starting treatment at 30 years of age. Costs and health
benefits are discounted at 6% and 1.5%, respectively.
Uncertainty analysis
We conducted multivariate Monte Carlo sensitivity
analysis for uncertainty in random variables, together
with scenario analysis of the management variables
within the model.26 We constructed a cost effectiveness
acceptability curve for the 20 year cost per QALY
gained for each treatment.
We examined the impact of setting the price of all
the drugs equal to the most cost effective treatment in
the base case. As existing cost effectiveness analyses
have adopted a wide range of time horizons, we exam›
ined the cost effectiveness as the time horizon
increased between one and 20 years.4–9
Results
The primary outcome was cost per QALY gained. The
price of each drug had a considerable effect on the
central estimate of cost effectiveness for each drug
(table 2). The use of a 6% discount rate for both costs
and benefits increased the cost per QALY gained by
around 75%.
Uncertainty analysis
The probability that the cost effectiveness of any of the
interventions is better than £20 000 ($32 250; &30 750)
is in the range 3% to 18% (fig 2). The fact that the curve
never reaches 1.0 implies that, given current evidence,
all of these drugs may lead to a reduction in quality
of life compared with conventional management.
Figure 3 shows the cost per QALY estimated by this
assessment for the treatment with the mid›range cost
effectiveness as the time horizon increases from one to
20 years, together with estimates from other previous
Table 1 Details of published trials of interferon betas and glatiramer acetate in multiple sclerosis
Trial No of patients Type of disease Intervention
Duration of follow
up (years)
Interferon beta Multiple Sclerosis Study Group14 372 Relapsing remitting Placebo versus 1.6 MIU/week or 8 MIU/week
interferon beta›1b
3
PRISMS15 560 Relapsing remitting Placebo versus 22 ìg/week or 44 ìg/week
interferon beta›1a
2
Jacobs et al16 301 Relapsing remitting Placebo versus 6 MIU/week interferon beta›1a 2
Johnson et al17 251 Relapsing remitting Placebo versus 20 ìg glatiramer acetate 2
European Study Group18 718 Secondary progressive Placebo versus 8 MIU interferon beta›1b 3
Box 3: Assumptions made in constructing
model
• A sustained effect of treatment was modelled on
both progression and relapse beyond the trial’s
duration. Any patient who stops treatment then
progresses according to rates for disease progression
under conventional management but retains any
benefits received at no additional cost of
treatment—on the expanded disability status scale,
these patients never catch up with the patients who
only receive conventional management
• The effects of treatment did not deteriorate or
increase over time
• The annual relative risk of all cause mortality for the
multiple sclerosis cohort was assumed to be the same
as a normal healthy population, minus the death
observed in the London Ontario cohort
• Patients start treatment according to the Association
of British Neurologist’s guidelines and are treated until
they reach state 7.0 or drop off treatment
Table 2 Cost per quality adjusted life year gained compared with conventional treatment for multiple sclerosis
Intervention Disease treated
Base case public
model (£)
6% discount rate
for costs and
benefits (£)
Equal price
(£7259)*
Base case
confidential model
Interferon beta›1a 6 MIU/week (Avonex) Relapsing remitting 42 041 73 137 30 473 —
Interferon beta›1a 22 ìg/week (Rebif) Relapsing remitting 60 963 105 718 44 811 —
Interferon beta›1a 44 ìg/week (Rebif) Relapsing remitting 71 732 124 034 35 685 —
Interferon beta›1b 8 MIU/week (Betaferon) Relapsing remitting 49 664 86 127 49 664 35 282
Glatiramer acetate 20 mg/week (Copaxone) Relapsing remitting 97 636 168 539 108 859 —
Interferon beta›1b 8 MIU/week (Betaferon) Relapsing remitting and
secondary progressive
44 390 78 722 44 390 39 872
*Price of all therapies set equal to price of therapy that was most cost effective in base case.
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assessments. The continuous line plots the cost per
QALY gained for the treatment with the mid›range
estimate of cost effectiveness generated by the consor›
tium’s model. A substantial proportion of the
difference between estimates of cost effectiveness can
be explained by the time horizon adopted in specific
assessments. Almost all the previous estimates of cost
effectiveness lie inside this line. For any given time
horizon the replication of previous estimates of the
cost effectiveness of these treatments requires the
adoption of more favourable assumptions. The excep›
tions to this are the estimates reported by Parkin and
Prosser, which are close to those produced by our
model.4 9
Discussion
The point estimates of the cost effectiveness of four
treatments (three interferon betas and glatiramer
acetate) improved considerably as the time horizon
increased; those at five years were broadly comparable
to previously published estimates.4 The estimates with
a 20 year time horizon were markedly lower, ranging
from £42 000 to £98 000 per QALY gained. Using the
commercial in›confidence estimates of efficacy, the
most favourable estimate is £35 000 per QALY and the
least favourable is £104 000 per QALY. These
estimates did not change substantially if the treatment
was assumed to start at diagnosis, rather than
according to current guidance from the Association of
British Neurologists, nor if patients were treated until
state 10 (death).3 Care must be exercised in comparing
these values, as not all the estimates of efficacy in the
public domain are based on intention to treat analyses.
We adopted assumptions that were favourable to treat›
ment. The values quoted assume that the efficacy
observed within the clinical trial period was main›
tained for as long as patients received treatment, and
also that patients who stopped treatment did not catch
up with those who never received treatment.
Most patients have stopped treatment by 10 years,
thus the assumption we have made about disease pro›
gression after stopping treatment has a major impact
on the estimate for cost effectiveness. If there is any
rebound effect after stopping treatment, the cost effec›
tiveness deteriorates.
The dataset used to estimate the costs in different
states is relatively small when the patients with primary
progressive and benign multiple sclerosis are removed.
It is possible that the true costs are markedly different
from those used in the baseline analysis, but there is no
evidence to support this. The dataset used to estimate
utilities for each health state is considerably larger. The
utility decrement for relapse may be an underestimate
as individuals experiencing severe relapses may be less
likely to complete or return the questionnaire. Since
the estimate may be biased towards moderate and mild
relapses, we specified a wide range for the uncertainty
in decrement of utility. The cost effectiveness estimates
are not sensitive to this value.
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What is already known on this topic
Interferon beta and glatiramer acetate are the only
disease modifying therapies used to treat multiple
sclerosis
Economic evaluations of these drugs have had
flaws in the specification of the course of the
disease, efficacy, duration of treatment, mortality,
and the analysis of uncertainty
None of the existing estimates of cost effectiveness
can be viewed as robust
What this study adds
The cost per quality adjusted life year gained is
unlikely to be less than £40 000 for interferon beta
or glatiramer acetate
Experience after stopping treatment is a key
determinant of the cost effectiveness of these
therapies
Key factors affecting point estimates of cost
effectiveness are the cost of interferon beta and
glatiramer acetate, the effect of these therapies on
disease progression, and the time horizon
evaluated
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The uncertainty surrounding each of these point
estimates of cost effectiveness is also large and derives
primarily from the uncertainty in the actual scale of
benefit gained from these interventions in terms of
delayed progression of disability. Further research to
establish the impact of these treatments by using
robust and stable outcome measures would be of con›
siderable value in improving the precision of estimates
for cost effectiveness.27 It would also be extremely valu›
able to obtain real data on the progress of people once
they have stopped treatment. Given the length of time
that these drugs have been in use, it should be possible
to gather such data. In the short term, the key modifi›
able determinant of the cost effectiveness of these
drugs is their price.
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Commentary: Evaluating disease modifying treatments in multiple
sclerosis
David H Miller
Multiple sclerosis is a chronic demyelinating disease of
the central nervous system that affects one in 800 people
in the United Kingdom. It usually presents in young
adults, and although the course is highly variable, most
people develop serious and irreversible neurological
disabilities over 10 to 30 years. It has a major adverse
impact on the quality of life of affected individuals and
their carers. The loss of productivity and independence
has important socioeconomic consequences.
Three interferon betas and glatiramer acetate are
licensed as disease modifying treatments for multiple
sclerosis. They are given by injection and have shown
few serious adverse effects over observation periods that
are currently up to 10 years. In placebo controlled trials
over two years, the agents reduced the relapse rate by
30%; interferon beta reduced the rate at which new
lesions were detected by magnetic resonance imaging by
50›80% and modestly slowed the accumulation of
disability in relapsing remitting but not secondary
progressive non›relapsing multiple sclerosis.1
The use of these agents has evoked debate. Firstly, it
is not known whether treatment in early relapsing
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remitting multiple sclerosis delays the development of
secondary progression and irreversible disability—
longer term studies are needed. Secondly, the
treatments are expensive, and in 2002 the National
Institute for Clinical Excellence concluded that they
were not cost effective.2 Chilcott et al performed the
health economics analysis for the National Institute for
Clinical Excellence and show that the cost per quality
adjusted life year gained is high but decreases with
prolonged treatment up to 20 years. This makes sense
because it takes many years to develop the disabilities
that account for the major costs of the disease. The
model is, however, weakened by extrapolating treat›
ment effects over longer periods than those for which
data are available, using a single study of the clinical
course of the disease to derive disease progression
rates, and by the unpredictability of the disease and the
difficulty in capturing all aspects of its impact on
patients.
In the face of such uncertainties, the Department of
Health has introduced a scheme for providing disease
modifying treatments in the NHS. This risk sharing
scheme provides treatment for ambulant patients with
clinically active relapsing disease,3 with annual moni›
toring of neurological status over 10 years, calculation
of cost effectiveness based on actual long term data,
and adjustment of the cost of the drugs (if required) to
make them cost effective. The scheme has important
scientific and practical limitations and will need
substantial investment to generate reliable data.
Nevertheless, it is a constructive approach in
addressing a difficult problem, and it is hard to see a
realistic alternative. Providing no disease modifying
treatments to patients with frequent and disabling
relapses would seem unreasonable, and a long term
placebo controlled trial is unlikely to be acceptable to
many patients or neurologists.
Research is needed to identify those who will ben›
efit most from disease modifying treatments. This may
be possible by independent meta›analysis of large
datasets from clinical and magnetic resonance imaging
studies derived from multiple trials and natural history
studies of the clinical course of multiple sclerosis.4
Work must also go on to develop more effective treat›
ments.
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